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We retrospectively conducted a study of men who
have sex with men who visited the Amsterdam, the
Netherlands, sexually transmitted diseases clinic from
January 2002 to December 2003 and had rectal Chlamydia
trachomatis infections. We found that symptomatic (73%)
as well as asymptomatic (43%) patients were infected with
a new C. trachomatis LGV variant. 
In December 2003, an unusual symptom of early lym-phogranuloma venereum (LGV) in a patient infected
with HIV-1, who also had proctitis, was reported in
Rotterdam (1). In the same city, an outbreak of LGV with
similar symptoms, such as proctitis and constipation, sub-
sequently was identified in men who have sex with men
(MSM) (2). Here we report 32 patients with, and 13 MSM
without, mucous membrane abnormalities in MSM with
confirmed LGV in 2002–2003.
LGV is a systemic disease caused by the Chlamydia
trachomatis serovars L1 to L3. More invasive than disease
caused by the urogenital serovars (D–K), LGV can mani-
fest as 1) an inguinal syndrome, with genital ulceration and
inguinal lymphadenopathy (buboes) and subsequent sup-
puration, and 2) an anogenitorectal syndrome, with procto-
colitis and hyperplasia of intestinal and perirectal
lymphatic tissue. Both syndromes can be accompanied by
systemic symptoms including fever, malaise, chills,
anorexia, myalgia, and arthralgia. If left untreated, the
infection can lead to fistulas, strictures, genital elephantia-
sis, frozen pelvis, and infertility (3). LGV is endemic in
Africa, Southeast Asia, and the Caribbean; it is a sporadic
disease in Europe and North America.
The Study
For this study, we selected MSM who were treated at
our sexually transmitted disease (STD) clinic (≈20,000
new consultations per year) in 2002 and 2003 with C. tra-
chomatis proctitis confirmed by a positive polymerase
chain reaction (PCR), COBAS AMPLICOR (Hoffman-La
Roche Ltd., Basel, Switzerland). Upon proctoscopic exam-
ination by 1 medical practitioner, patients were designated
into 2 groups: 1 group with mucous membrane abnormal-
ities (MMA+, n = 44) when mucopurulent anal discharge
or bloody, ulcerative rectal lesions were found, and 1
group without MMA (MMA–, n = 30) when those symp-
toms were not found. Samples were taken by proctoscopic
examination. During the study, C. trachomatis proctitis
was diagnosed in some patients at separate times. Those
follow-up samples were excluded from the study.
Calculations are based on the number of patients in whom
C. trachomatis proctitis was diagnosed during their first
visit. Patients were treated with a single dose of 1 g
azithromycin, the consensus treatment for uncomplicated
urogenital C. trachomatis infections at that time. Purified
C. trachomatis DNA obtained from the rectal samples of
these 74 patients was used to assess C. trachomatis
serovars identified by PCR, based on restriction fragment
length polymorphism (RFLP) analysis of the ompA gene
as described previously (4,5). In addition, we sequenced
the complete ompA gene to identify possible changes at the
nucleotide level (ABI 310 automated sequencer, PE
Biosystems, Nieuwerkerk a/d IJssel, the Netherlands). The
exact sequence methods and primers are described by
Morré et al. (5). In short,  ompA nucleotide sequence
analysis was performed in several sequence reactions gen-
erating the complete 1.1-kbp order. DNA sequencing was
performed in both directions and analyzed by automated
DNA sequencing on an ABI 310 sequencer. Sequences
were aligned with the BioEdit Sequence Alignment Editor
(Ibis Therapeutics, Carlsbad, CA, USA). Reference
sequences were derived from GenBank
(www.ncbi.nlm.nih.gov/GenBank). 
Serum samples from these patients, taken at consulta-
tion and stored at –20°C, were used to measure C. tra-
chomatis–specific immunoglobulin (Ig) G. This C.
trachomatis–IgG peptide enzyme-linked immunosorbent
assay (pELISA) (Medac Diagnostika mbH, Hamburg,
Germany) is based on a synthetic peptide from an immun-
odominant region of the major outer membrane protein
and was performed according to the manufacturer’s
instructions, as described previously (6). A titer of both
ELISAs of ≥1:50 was considered positive, and an arbitrary
differentiation was made between low (1:50–1:200) and
high titers (>1:200).
Genotyping the ompA gene by RFLP of these 74
patients showed that 45 samples were positive for
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C. trachomatis all type L2 (Table). Sequencing of the ompA
gene demonstrated that all L2-positive samples contained a
new (based on the National Center for Biotechnology
Information BLAST queries) C. trachomatis genovariant
(Figure), which we designated L2b. The novel sequence
was deposited in GenBank (accession no. AY586530).
When the ompA sequences of these patients were com-
pared to the prototype sequences of L2 and its variants L2a
and L2′, besides 2 already described changes, a new base
pair change was found. One change in variable segment 2
was deducted from L2a and L2′, and one from L2. The
third change has not been described before. All nucleotide
changes resulted in amino acid substitutions. The fourth
change was found in constant segment 2 (CS-2) at amino
acid 157: the third nucleotide is G in L2b and L1, C in L2,
and A in L3. As expected, this mutation is conserved, and
all combinations encode for the amino acid glycine.
Combining the sequence data with the RFLP typing
showed that 32 of 44 samples from MMA+ and 13 of 30
samples from MMA– patients were L2b. In the MMA+
patient group, a positive chlamydia serologic test results
mainly an IgG titer 1:>200, correlated well with the LGV
diagnosis. Approximately 80% of all LGV patients had
high titers; in the MMA– group, species-specific C. tra-
chomatis serologic test results did not correlate with LGV.
The patients’ characteristics are shown in the Table.
Median age of the 45 men with samples positive for C. tra-
chomatis was 35.8 years (range 25.9–47.6) compared with
38.1 years (range 25.8–58.2) for the men with samples
negative for C. trachomatis. All C. trachomatis–positive
patients lived in the Netherlands, most in Amsterdam, and
most were of Dutch ethnic background. 
Anal discharge was reported by 15 of 20 patients with
LGV. Genital ulcers (all localized to the perianal area) and
inguinal lymphadenopathy were found in only a few
patients. Ulcers in the 2 patients infected with a non-LGV
C. trachomatis strain were caused by herpes simplex virus
2 and Treponema pallidum. In the 3 ulcers found in the
MMA+ patients, the L2b C. trachomatis strain was found.
The mean number of previously documented sexually
transmitted infection episodes was 8.3 among the MMA+
LGV patients in contrast to 5.8 episodes in the non-LGV
patients. Twenty-four of 30 of the MMA+ LGV patients
and 7 of 14 of the MMA– LGV patients were HIV-infect-
ed. All patients with a retrospective diagnosis of LGV were
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Figure. Schematic representation of the Chlamydia trachomatis
ompA gene. In detail variable segment 2 (VS-2): nucleotide and
amino acid (aa) sequence comparison of the prototypes L1, L2,
L2 , L2a, and L3 and the newly identified lymphogranuloma
venereum (LVG) strain, which we designated L2b. Conserved
nucleotides in VS-2 for all LGV strains are shown in red. The
nucleotide substitutions in L2b as compared to all LGV strains is
indicated by arrows. All aa encoded by the substitution combina-
tions are indicated. CS = constant segment; omp = outer mem-
brane protein.
contacted and offered reexamination. If the L2b strain per-
sisted, the patients received doxycycline, 100 mg twice
daily for 3 weeks, the consensus treatment for LGV. 
Conclusions
We conclude the following: 1) the outbreak of LGV
among MSM in the Netherlands expands beyond the clus-
ter reported earlier in Rotterdam and can be traced back to
at least January 2002; 2) the outbreak in Amsterdam and
possibly the one in  Rotterdam was caused by a newly
identified L2b variant; 3) both MMA+ and MMA– men
are infected with C. trachomatis and most of them are
HIV-positive; 4) species-specific serology can help sup-
port the LGV diagnosis when clinical symptoms are pres-
ent but cannot be used to detect LGV-infected persons who
are asymptomatic.
Although based upon a small, select population, our
results justify additional study of high-risk core groups
who transmit this LGV genovariant to determine transmis-
sion risk factors and diagnostic criteria. The outbreak of
LGV is ongoing; we currently see 1–2 new patients per
week at our STD clinic.
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